These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 35214083)
1. Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Ries M; Moulari B; Shetab Boushehri MA; Ali ME; Molnar D; Béduneau A; Pellequer Y; Lamprecht A Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214083 [TBL] [Abstract][Full Text] [Related]
2. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. Moulari B; Béduneau A; Pellequer Y; Lamprecht A J Control Release; 2014 Aug; 188():9-17. PubMed ID: 24910194 [TBL] [Abstract][Full Text] [Related]
3. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. Pedersen G Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335 [TBL] [Abstract][Full Text] [Related]
4. Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. Wachsmann P; Lamprecht A Methods Enzymol; 2012; 508():377-97. PubMed ID: 22449936 [TBL] [Abstract][Full Text] [Related]
6. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Wang X; Yan J; Wang L; Pan D; Xu Y; Wang F; Sheng J; Li X; Yang M Theranostics; 2020; 10(23):10808-10822. PubMed ID: 32929381 [No Abstract] [Full Text] [Related]
7. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273 [TBL] [Abstract][Full Text] [Related]
8. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852 [TBL] [Abstract][Full Text] [Related]
9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
10. A Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082 [TBL] [Abstract][Full Text] [Related]
11. Surfactant-dependence of nanoparticle treatment in murine experimental colitis. Wachsmann P; Moulari B; Béduneau A; Pellequer Y; Lamprecht A J Control Release; 2013 Nov; 172(1):62-68. PubMed ID: 23933520 [TBL] [Abstract][Full Text] [Related]
12. Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease. Zhang S; Langer R; Traverso G Nano Today; 2017 Oct; 16():82-96. PubMed ID: 31186671 [TBL] [Abstract][Full Text] [Related]
13. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy]. Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355 [TBL] [Abstract][Full Text] [Related]
14. Small but powerful: will nanoparticles be the future state-of-the-art therapy for IBD? Lechner K; Zeeshan M; Noack M; Ali H; Neurath MF; Weigmann B Expert Opin Drug Deliv; 2022 Mar; 19(3):235-245. PubMed ID: 35184617 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. Yang C; Merlin D Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785 [TBL] [Abstract][Full Text] [Related]
16. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138 [TBL] [Abstract][Full Text] [Related]
17. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636 [TBL] [Abstract][Full Text] [Related]
18. Crohn's targeted therapy: myth or real goal? Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597 [TBL] [Abstract][Full Text] [Related]
19. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases. Youshia J; Lamprecht A Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060 [TBL] [Abstract][Full Text] [Related]
20. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]